Use of PRAME-specific cytotoxic T cells might be a strategy for a sizable subgroup of patients with DLBCL exploiting the concept of EZH2 inhibition–mediated enhancement of PRAME expression and TAA presentation. This evidence concerns the gene PRAME and diffuse large B-cell lymphoma.